← ANALYST RATINGS · TIPRANKS
Pulse Biosciences (PLSE): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $62.33, the highest $73.00, the lowest $55.00. The average is +40.3% from the last price of $44.43.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Instruments and SuppliesxAI Grok-3 | TipRanks - xAI | $52.00 → $51.00−1.9% | Hold | +14.8% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI DeepSeek Medical - Instruments and SuppliesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $51.00 → $49.00−3.9% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI OpenAI Medical - Instruments and SuppliesOpenAI 5.2 | TipRanks - OpenAI | $50.00 → $49.00−2.0% | Hold | +10.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Anthropic Medical - Instruments and SuppliesAnthropic Opus-4.5 | TipRanks - Anthropic | $51.00 → $50.00−2.0% | Hold | +12.5% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Google Medical - Instruments and SuppliesGemini 3-pro | TipRanks - Google | $53.00 → $52.00−1.9% | Hold | +17.0% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI PerPlexity Medical - Instruments and SuppliesPerPlexity SonarPro | TipRanks - PerPlexity | $50.00 → $48.00−4.0% | Hold | +8.0% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | $35.00 → $60.00+71.4% | Buy | +35.0% | Reiterated | 13.10.26on TipRanks 07:50 | −7.4%next day −3.5% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $45.00 → $55.00+22.2% | Buy | +23.8% | Assigned | 13.10.26on TipRanks 07:35 | −7.4%next day −3.5% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $70.00 | Buy | +57.6% | Reiterated | 06.10.26on TipRanks Oct 7 06:08 | −2.0%next day −1.1% · 5 days −2.3% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $58.00 | Buy | +30.5% | Reiterated | 06.10.26on TipRanks 06:50 | −2.0%next day −1.1% · 5 days −2.3% | ↗ |
| Keith Hinton★★★★★★★★★★#7123 · hits 80% · avg +7.0% | Freedom Capital Markets | $73.00 | Buy | +64.3% | Initiated | 09.09.26on TipRanks 06:30 | +9.0%next day +3.4% · 5 days −5.2% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $12.56 → $58.00+361.8% | Buy | +30.5% | Initiated | 17.08.26on TipRanks 06:51 | +5.5%next day −1.0% · 5 days +6.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Pulse Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.00 at a price of $49.92 (+8.2%); now: $62.33 at $44.43 (+40.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 0 | 1 | 3 | 6 | 7 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.31 (from $-0.36 to $-0.28). Last quarter: $-0.28.
Sales
Next quarter’s sales estimate — $1M (from $0M to $1M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Pulse Biosciences
- CEO: Paul Arthur LaViolette
- Employees: 116
- 601 Brickell Key Drive, Miami, FL, 33131, US
- www.pulsebiosciences.com
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Data from the stock’s TipRanks forecast page, read 70 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗